920P - VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients in the thalidomide era

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Plasma Cell Dyscrasias
Presenter Leisa Lopes-Aguiar
Citation Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375
Authors L. Lopes-Aguiar1, M.T. Delamain2, A.B.C. Brito3, G.J. Lourenço3, E.F.D. Costa3, G.B. Oliveira2, J. Vassallo4, C.A. De Souza2, C.S.P. Lima3
  • 1Department Of Internal Medicine, Faculty of Medical Sciences, University of Campinas, 13083888 - Campinas/BR
  • 2Haematology And Haemotherapy Centre, University of Campinas, Campinas/BR
  • 3Department Of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas/BR
  • 4Laboratory Of Molecular And Investigative Pathology, Faculty of Medical Sciences, University of Campinas, Campinas/BR



Angiogenesis (AG) abnormalities are crucial in pathogenesis of multiple myeloma (MM), and give support to treat patients with antiangiogenic agents. However, patients with similar clinicopathological aspects may present distinct outcome under AG inhibitors treatment. Single nucleotide polymorphisms (SNPs) in genes involved in blood vessels formation may constitute a plausible explanation for this finding. This study aimed to investigate the roles of VEGF c.-2595C > A (rs699947), c.-1154G > A (rs1570360), c.-634G > C (rs2010963), c.*237C > T (rs3025039), VEGFR2 c.-906T > C (rs2071559) and c.889G > A (rs2305948) SNPs, and GSTM1 and GSTT1 genes in outcome of MM patients treated with thalidomide-based regimen.


The study comprised 102 MM patients diagnosed between June 2005 and June 2013. The tumor was diagnosed and staged by standard criteria. Therapeutic regimens consisted in thalidomide combined with steroids and chemotherapy, followed or not by autologous steam cell transplantation. Response was evaluated at the end of therapy using the International Myeloma Working Group guidelines. Genotypes were analyzed in genomic DNA by polymerase chain reaction based methods. The chi-square test and logistic regression model were used to identify variables influencing response to therapy. Survival was estimated by Kaplan-Meier method, log-rank test and Cox hazards models.


Patients with the wild-type allele of VEGF c.-2595C > A alone or plus the wild-type allele of VEGFR2 c.-906T > C SNPs, and the CGGC haplotype of all respective VEGF SNPs had 3.55, 9.91, and 3.86 more chances of achieving better response to therapy than others. At 60 months of follow-up, patients with VEGFR2 c.889GG, VEGF c.-634GG plus VEGFR2 c.889GG, and VEGFR2 c.889GG plus GSTM1 present genotypes had 2.62, 2.64, and 2.80 more chances of presenting disease relapse or progression, and 2.21, 4.88, and 4.23 more chances of evolving to death in multivariate analysis, respectively.


Our data present, for the first time, a preliminary evidence that VEGF c.-2595C > A, c.-1154G > A, c.-634G > C, c.*237C > T, VEGFR2 c.-906T > C and c.889G > A SNPs, and GSTM1 gene alter outcome of MM patients under thalidomide therapy.

Clinical trial identification

Not applicable

Legal entity responsible for the study

University of Campinas




All authors have declared no conflicts of interest.